235.00

1.74% -4.15

Quest Diagnostics Inc (DGX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Quest Diagnostics Inc stock is traded at $235.00, with a volume of 800.03K. It is down -1.74% in the last 24 hours and down -4.89% over the past month. Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Previous Close:

$239.15

Open:

$239.67

24h Volume:

800.03K

Relative Volume:

0.78

Market Cap:

$25.94B

Revenue:

$11.28B

Net Income/Loss:

$1.07B

P/E Ratio:

25.92

EPS:

9.0657

Net Cash Flow:

$1.33B

1W Performance:

+1.74%

1M Performance:

-4.89%

6M Performance:

+22.74%

1Y Performance:

+25.79%

1-Day Range:

$233.56

$240.75

1-Week Range:

$228.66

$240.75

52-Week Range:

$171.18

$248.84

Quest Diagnostics Inc Stock (DGX) Company Profile

Name

Quest Diagnostics Inc

Sector

Healthcare (1052)

Industry

Diagnostics & Research (44)

Phone

(973) 520-2700

Address

500 PLAZA DRIVE, SECAUCUS

Employee

57,000

Twitter

@QuestDX

Next Earnings Date

2026-10-22

Latest SEC Filings

DGX's Discussions on Twitter

Compare DGX vs TMO, DHR, NTRA, A, IDXX

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DGX Quest Diagnostics Inc	235.00	25.94B	11.28B	1.07B	1.33B	9.0657
TMO Thermo Fisher Scientific Inc	690.00	255.13B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	229.04	161.01B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	393.44	56.71B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	172.97	48.77B	7.23B	1.41B	1.09B	4.979
IDXX Idexx Laboratories Inc	560.36	44.15B	4.45B	1.10B	1.06B	13.59

Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Upgrade	Barclays	Equal Weight → Overweight
Aug-25-25	Downgrade	Robert W. Baird	Outperform → Neutral
Apr-02-25	Initiated	Redburn Atlantic	Buy
Mar-04-25	Downgrade	Citigroup	Buy → Neutral
Jan-06-25	Upgrade	Leerink Partners	Market Perform → Outperform
Dec-17-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-10-24	Resumed	Jefferies	Buy
Oct-23-24	Upgrade	Robert W. Baird	Neutral → Outperform
Aug-28-24	Resumed	Evercore ISI	In-line
Jul-10-24	Upgrade	Citigroup	Neutral → Buy
Feb-26-24	Initiated	Leerink Partners	Market Perform
Feb-07-24	Upgrade	Jefferies	Hold → Buy
Jan-03-24	Initiated	Barclays	Equal Weight
Dec-12-23	Upgrade	BofA Securities	Neutral → Buy
Jun-29-23	Initiated	Piper Sandler	Neutral
May-02-23	Downgrade	BofA Securities	Buy → Neutral
Apr-03-23	Upgrade	Citigroup	Sell → Neutral
Jan-23-23	Initiated	Evercore ISI	In-line
Nov-17-22	Downgrade	Citigroup	Neutral → Sell
Aug-22-22	Resumed	Morgan Stanley	Equal-Weight
Apr-04-22	Downgrade	Citigroup	Buy → Neutral
Feb-23-22	Downgrade	UBS	Buy → Neutral
Feb-02-22	Downgrade	Jefferies	Buy → Hold
Jan-28-22	Downgrade	Deutsche Bank	Buy → Hold
May-04-21	Upgrade	UBS	Neutral → Buy
Mar-12-21	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-21-20	Upgrade	Argus	Hold → Buy
Jul-29-20	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Jul-14-20	Upgrade	BofA Securities	Neutral → Buy
Jun-09-20	Upgrade	Wells Fargo	Underweight → Equal Weight
Jun-02-20	Upgrade	Deutsche Bank	Hold → Buy
Apr-28-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-27-20	Upgrade	Citigroup	Neutral → Buy
Apr-27-20	Upgrade	Wolfe Research	Underperform → Peer Perform
Mar-27-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-08-20	Initiated	Wells Fargo	Underweight
Jan-07-20	Downgrade	Barclays	Overweight → Equal Weight
Dec-19-19	Upgrade	BofA/Merrill	Underperform → Neutral
Jul-15-19	Downgrade	Goldman	Neutral → Sell
Apr-02-19	Upgrade	Jefferies	Hold → Buy
Mar-18-19	Resumed	Credit Suisse	Neutral
Jan-31-19	Downgrade	Argus	Buy → Hold
Jan-17-19	Initiated	UBS	Neutral
Jan-03-19	Downgrade	BofA/Merrill	Neutral → Underperform
Dec-03-18	Downgrade	BofA/Merrill	Buy → Neutral
Nov-30-18	Downgrade	Goldman	Buy → Neutral

View All

Quest Diagnostics Inc Stock (DGX) Latest News

Oct 15, 2026

Quest Diagnostics Incorporated (DGX) Options ChainYahoo Finance - Yahoo! Finance Canada

Oct 15, 2026

Quest Diagnostics shares may shift 4.4% on Oct. 22 earnings - Investing.com

Oct 15, 2026

Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance

Oct 15, 2026

Oct 14, 2026

Quest Continues to Enjoy a Narrow Moat Thanks to Its Status as Low-Cost Producer - Morningstar

Oct 14, 2026

Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Oct 14, 2026

Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo! Finance Canada

Oct 14, 2026

Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings - Zacks Investment Research

Oct 14, 2026

Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings - TradingView

Oct 14, 2026

Oct 09, 2026

Quest Diagnostics (NYSE:DGX): A Dividend Quality Pick for Income Investors - ChartMill

Oct 09, 2026

Oct 08, 2026

Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 08, 2026

Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 08, 2026

Leerink Partners Adjusts Quest Diagnostics Price Target to $265 From $254 - www.marketscreener.com

Oct 08, 2026

Oct 07, 2026

Quest Diagnostics Incorporated (DGX) options chain - Yahoo Finance UK

Oct 07, 2026

Oct 06, 2026

Quest Diagnostics (DGX) Announces Executive Leadership Transitio - GuruFocus

Oct 06, 2026

Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Oct 06, 2026

Catherine T. Doherty to Transition to EVP at Quest Diagnostics, Retirement Set for July 2027 - TradingView

Oct 06, 2026

Barclays Adjusts Price Target on Quest Diagnostics to $260 From $250, Keeps Overweight Rating - marketscreener.com

Oct 06, 2026

Evercore ISI Adjusts Price Target on Quest Diagnostics to $235 From $240, Keeps In Line Rating - www.marketscreener.com

Oct 06, 2026

Quest Diagnostics Inc's Dividend Analysis - Yahoo Finance

Oct 06, 2026

Quest Diagnostics (NYSE:DGX) Rides Steady Testing Demand - Kalkine Media

Oct 06, 2026

Oct 05, 2026

Quest Diagnostics’ Quarterly Earnings Preview: What You Need to Know - Yahoo Finance

Oct 05, 2026

Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus - Zacks Investment Research

Oct 05, 2026

Oct 03, 2026

DGX5874579 Bond Profile: Coupon and Redemption - TradingView

Oct 03, 2026

Oct 02, 2026

Three Days Left To Buy Quest Diagnostics Incorporated (NYSE:DGX) Before The Ex-Dividend Date - Moomoo

Oct 02, 2026

Quest Diagnostics (NYSE:DGX) Breakout Setup Backed by Technical Rating 7 and Setup Rating 8 - ChartMill

Oct 02, 2026

Oct 01, 2026

Quest Diagnostics (DGX) Highlights Haystack MRD Test Accuracy in Colorectal Cancer Trials - GuruFocus

Oct 01, 2026

Sep 29, 2026

Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Sep 29, 2026

Sep 25, 2026

Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? - TradingView

Sep 25, 2026

Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? - Yahoo Finance

Sep 25, 2026

Sep 24, 2026

Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments - GlobeNewswire Inc.

Sep 24, 2026

Sep 23, 2026

Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch - Yahoo Finance

Sep 23, 2026

Quest Diagnostics shows growth potential despite Medicare uncertainties, driven by testing demand and acquisitions. - Pluang

Sep 23, 2026

Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds - Seeking Alpha

Sep 23, 2026